Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility Study

计划入组 30 人 · 首次发布于 2024 年 11 月 8 日

STAR Trial (Siegel Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis)

计划入组 1,025 人 · 首次发布于 2025 年 12 月 12 日

TAVR for Aortic Valve Disease

计划入组 5,000 人 · 首次发布于 2022 年 6 月 30 日

Warfarin(Coumadin, Jantoven)

C₁₉H₁₆O₄ · Rx

Cefazolin

C₁₄H₁₄N₈O₄S₃ · Rx

TAVO-317A

THUBRIKAR AORTIC VALVE INC

United States

HERSHEY VALVE CO., LTD.

Taiwan

VENUS MEDTECH-B

Hong Kong, China

Boston Scientific Invests $1.5 Billion in MiRus for Revolutionary Nickel-Free TAVR Technology

FDA Clears Pi-Cardia's ShortCut Device for Valve-in-Valve TAVR Procedures

TAVR Rewrites Structural Heart Care as Heart Valve Devices Market Projects 11.2% CAGR Through 2032